GW Pharmaceuticals has appointed three new independent members to its Board of Directors, bringing the GW Board to a total of eight members. Joining the Board of Directors are Catherine Mackey, Alicia Secor and Lord William Waldegrave. Catherine is an experienced corporate executive, director and advisor with over thirty years of accomplishment in the biotechnology, pharmaceutical, and agricultural industries. She is currently Chief Executive Officer of CYPrus Therapeutics, Inc. and Chairman of the Board of Cour Pharmaceutical Development. Alicia Secor is currently President and Chief Executive Officer of Juniper Pharmaceuticals. Lord Waldegrave served as a Conservative Member of the British Parliament from 1979 to 1997 including sixteen years as a Government Minister, of which seven years were as a Cabinet Minister (Minister of Agriculture, Chief Secretary of the Treasury, Secretary of State for Health, and Chancellor of the Duchy of Lancaster with responsibility for the Civil Service Reform and Science). From 1998–2015, he served as Chairman of Biotechnology Growth Trust plc. Lord Waldegrave was appointed Chairman of Coutts in January 2014 and is Chairman of the Royal Mint Advisory Committee, former Chairman of the Rhodes Trust, a Founder Trustee of the Mandela Rhodes Foundation (South Africa), and a former Chairman of the National Museum of Science and Industry.
